Moderna's stock is rising, with some outlets suggesting it may be a good buy after a key FDA win. However, others are questioning whether the stock's surge has already made it too late to invest. The company's performance is being compared to other major biotech companies, with some predictions of further growth, while others are offering a more cautionary view of its prospects.